Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

Impact · against what's priced in

Propanc Biopharma is expanding the potential utility of its lead candidate PRP into fibrosis and chemotherapy-resistant cancers, while providing a timeline for First-In-Human studies in 2026. These developments increase the long-term total addressable market and provide a concrete clinical milestone for investors.

PPCB+0.40

No priced-in read yet